2-氯-6-硝基-3-丙基喹啉 | 610320-23-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 2-氯-6-硝基-3-丙基喹啉
• 英文名称: 2-chloro-3-propyl-6-nitroquinoline
• 英文别名: 2-Chloro-6-nitro-3-propylquinoline
• CAS: 610320-23-5
• 化学式: C₁₂H₁₁ClN₂O₂
• 分子量: 250.685
• InChiKey: JJHFBNDOVWEOFB-UHFFFAOYSA-N

物化性质

• 沸点：
  388.0±37.0 °C(Predicted)
• 密度：
  1.320±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  58.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-氯-6-硝基-3-丙基喹啉 在 硫酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 6-硝基-2-哌嗪-1-基-3-丙基喹啉
  参考文献：
  名称：

  Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter: Part 3. † †Part 2. See ref 1. A potential 5-HT transporter imaging agent, 3-(3-[ 18 F]fluoropropyl)-6-nitroquipazine

  摘要：

  3-(3-[F-18]Fluoropropyl)-6-nitroquipazine ([F-18]FPNQ) as a 5-HT transporter imaging agents was designed, synthesized, and evaluated. FPNQ was selected due to its potent in vitro biological activity (K-i = 0.32 nM) in rat brain cortical membranes. The F-18-labeled FPNQ was prepared by reaction of the propyl mesylate as a precursor with tetra-n-butylammonium [F-18]fluoride generated under NCA conditions. The precursor mesylate was synthesized from commercially available hydrocarbostyril in nine steps in 21% overall yield. The specific activity of the [F-18]FPNQ determined by radioreceptor assay was 27.0 GBq/mumol. Tissue distribution studies in mice showed the highest uptake in the frontal cortex (5.79 %ID/g) at 60 min post-injection. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2003.09.009
• 作为产物：
  描述：

  3-propyl-6-nitro-3,4-dihydro-2(1H)-quinolinone 在 2,3-二氯-5,6-二氰基-1,4-苯醌 、 三氯氧磷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 以95%的产率得到2-氯-6-硝基-3-丙基喹啉
  参考文献：
  名称：

  Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter: Part 3. † †Part 2. See ref 1. A potential 5-HT transporter imaging agent, 3-(3-[ 18 F]fluoropropyl)-6-nitroquipazine

  摘要：

  3-(3-[F-18]Fluoropropyl)-6-nitroquipazine ([F-18]FPNQ) as a 5-HT transporter imaging agents was designed, synthesized, and evaluated. FPNQ was selected due to its potent in vitro biological activity (K-i = 0.32 nM) in rat brain cortical membranes. The F-18-labeled FPNQ was prepared by reaction of the propyl mesylate as a precursor with tetra-n-butylammonium [F-18]fluoride generated under NCA conditions. The precursor mesylate was synthesized from commercially available hydrocarbostyril in nine steps in 21% overall yield. The specific activity of the [F-18]FPNQ determined by radioreceptor assay was 27.0 GBq/mumol. Tissue distribution studies in mice showed the highest uptake in the frontal cortex (5.79 %ID/g) at 60 min post-injection. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2003.09.009

文献信息

• Quinoline derivatives, their preparation and pharmaceutical compositions comprising the same
  申请人：Chi Dae-Yoon

  公开号：US20050165006A1

  公开（公告）日：2005-07-28

  Novel quinoline derivatives were prepared and evaluated their pharmaceutical activities. The quinoline derivatives according to the present invention effectively bind serotonin transporter (SERT) which is called serotonin reuptake site. Serotonin is one of the neurotransmitter and the lack of its concentration in synapse cause the depression. The quinoline derivatives in this invention can interrupt reuptake of serotonin into presynaptic neuron resulting the increasement of concentration of serotonin in synapse as well as stimulating the signal through the binding with serotonin recepter. Thus, they can be used for the prevention and treatment of mental disorder, especially depression, caused by the deficiency of serotonin concentration in synapse.

  通过本发明制备了新型喹啉衍生物，并评估了它们的药物活性。本发明的喹啉衍生物能够有效地结合血清素转运体（SERT），也称为血清素再摄取位点。血清素是一种神经递质，如果突触中缺乏其浓度，则会导致抑郁症。本发明中的喹啉衍生物可以中断血清素重新摄取到突触前神经元中，从而增加突触中血清素的浓度，并通过与血清素受体结合刺激信号。因此，它们可以用于预防和治疗由突触中血清素浓度不足引起的心理障碍，特别是抑郁症。
• [EN] QUINOLINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME<br/>[FR] DERIVES DE QUINOLINE, PREPARATIONS DE CES DERIVES ET COMPOSITIONS PHARMACEUTIQUES COMPRENANT CES DERIVES
  申请人：CHEMON INC

  公开号：WO2003082286A1

  公开（公告）日：2003-10-09

  Novel quinoline derivatives were prepared and evaluated their pharmaceutical activities. The quinoline derivatives according to the present invention effectively bind serotonin transporter (SERT) which is called serotonin reuptake site. Serotonin is one of the neurotransmitter and the lack of its concentration in synapse cause the depression. The quinoline derivatives in this invention can interrupt reuptake of serotonin into presynaptic neuron resulting the increasement of concentration of serotonin in synapse as well as stimulating the signal through the binding with serotonin recepter. Thus, they can be used for the prevention and treatment of mental disorder, especially depression, caused by the deficiency of serotonin concentration in synapse.
• Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter: Part 3. † †Part 2. See ref 1. A potential 5-HT transporter imaging agent, 3-(3-[ 18 F]fluoropropyl)-6-nitroquipazine
  作者：Byoung Se Lee、Soyoung Chu、Kyo Chul Lee、Bon-Su Lee、Dae Yoon Chi、Yearn Seong Choe、Sang Eun Kim、Yun Seon Song、Changbae Jin

  DOI：10.1016/j.bmc.2003.09.009

  日期：2003.11

  3-(3-[F-18]Fluoropropyl)-6-nitroquipazine ([F-18]FPNQ) as a 5-HT transporter imaging agents was designed, synthesized, and evaluated. FPNQ was selected due to its potent in vitro biological activity (K-i = 0.32 nM) in rat brain cortical membranes. The F-18-labeled FPNQ was prepared by reaction of the propyl mesylate as a precursor with tetra-n-butylammonium [F-18]fluoride generated under NCA conditions. The precursor mesylate was synthesized from commercially available hydrocarbostyril in nine steps in 21% overall yield. The specific activity of the [F-18]FPNQ determined by radioreceptor assay was 27.0 GBq/mumol. Tissue distribution studies in mice showed the highest uptake in the frontal cortex (5.79 %ID/g) at 60 min post-injection. (C) 2003 Elsevier Ltd. All rights reserved.